Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7MYO0
|
|||
| Drug Name |
AZD6793
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Phase 1 | [1] | |
| Company |
AstraZeneca
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05662033) A Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Ascending Doses in Healthy Subjects, an Open-label Study to Assess the Relative Bioavailability and Food Effect of a Tablet Formulation of AZD6793 in Healthy Subjects and a Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Tablet Formulation of AZD6793 in Patients With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AstraZeneca | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.